Format

Send to

Choose Destination
Sci Rep. 2018 Jun 12;8(1):8990. doi: 10.1038/s41598-018-25583-6.

Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.

Author information

1
Department of Gynecology and Obstetrics, Chinese PLA General Hospital, Beijing, P.R. China.
2
Department of Gynecology and Obstetrics, The 306th Hospital of PLA, Beijing, P.R. China.
3
Beijing Genecast Biotechnology Co., Beijing, P.R. China.
4
Department of Gynecology and Obstetrics, Peking University International Hospital, Beijing, P.R. China.
5
Department of Gynecology and Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, P.R. China.
6
Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China. zhhbao@ccmu.edu.cn.
7
Beijing Genecast Biotechnology Co., Beijing, P.R. China. zhhbao@ccmu.edu.cn.
8
Department of Gynecology and Obstetrics, Chinese PLA General Hospital, Beijing, P.R. China. meng6512@vip.sina.com.

Abstract

The goal of this work was to investigate the tumor mutational burden (TMB) in Chinese patients with gynecologic cancer. In total, 117 patients with gynecologic cancers were included in this study. Both tumor DNA and paired blood cell genomic DNA were isolated from formalin-fixed paraffin-embedded (FFPE) specimens and blood samples, and next-generation sequencing was performed to identify somatic mutations. TP53, PTEN, ARID1A, and PIK3CA alterations were significantly different in various types of gynecologic cancers (p = 0.001, 1.15E-07, 0.004, and 0.009, respectively). The median TMB of all 117 gynecologic tumor specimens was 0.37 mutations/Mb, with a range of 0-41.45 mutations/Mb. Despite the lack of significant difference, endometrial cancer cases had a higher median TMB than cervical and ovarian cancer cases. Younger gynecologic cancer patients (age <40 years) had a significantly lower TMB than older patients (age ≥40 years) (p = 0.04). In addition, TMB was significantly increased with increasing clinical stage of disease (p = 0.001). PTEN alterations were commonly observed in patients with a moderate to high TMB (n = 8, 38.10%, p = 9.95E-04). Although limited by sample size, all of the patients with TSC2 (n = 3, p = 3.83E-11) or POLE (n = 2, p = 0.005) mutations had a moderate to high TMB. Further large-scale, prospective studies are needed to validate our findings.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center